Kinnate Biopharma Inc. Profile Avatar - Palmy Investing

Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma…

Biotechnology
US, San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Kinnate Biopharma Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of KNTE's Analysis
CIK: 1797768 CUSIP: 49705R105 ISIN: US49705R1059 LEI: - UEI: -
Secondary Listings
KNTE has no secondary listings inside our databases.